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The F, hybrids of the autoimmune New Zealand Black (NZB) mice and the
phenotypically normal New Zealand White (NZW) mouse strain, develop severe
systemic autoimmune disease, more fulminant than that found in the parental
NZB strain. These mice manifest several immune abnormalities including anti-
bodies to nuclear antigens and subsequent development of a fatal, immune
complex-mediated glomerulonephritis with female predominance, remarkably
similar to systemic lupus erythematosus (SLE) in humans.
As a reflection oftheirautoimmune nature, boththe humanand murine forms
of the disease show a strong association with MHC gene products. HLA DR2
and HLA DR3 individuals are at a higher risk than the general population to
develop SLE (1), while in NZB/W F, mice (H-2d/°) a gene linked to the H-2u
haplotype derived from the NZW parent contributes to the development of the
lupus-like nephritis (2). The role of MHC genes in SLE and murine lupus is
unknown. Similarly, it has been difficult to clarify the regulatory and functional
abnormalities in the immune system that allow the tissue damage to occur in
autoimmune disease. No doubt, with the large range of cellular interactions
required fornormal immunological functionand tolerance, defects inthe control
or modulation ofthese interactions could occur at several levels and at any or all
ofthese might result in reactivity to self antigens.
In this study we pursue the hypothesis that IFN--t plays a crucial role in the
pathogenesis of autoimmune processes. Earlier reports from this laboratory (3)
and from others (4-5) have indicated that treatment of NZB/W F, mice with
partially purified type I or type II interferon, resulted in an increased incidence
of glomerulonephritis and death. If this hypothesis is correct, administration of
IFN-y may upregulate the autoimmune process, while blocking the effect of
IFN-y might downregulate such a process. We have tested this hypothesis in
vivo, in the NZB X NZW/F, lupus nephritis murine model.
Materials and Methods
IFN-y and Treatment Regimen. Murine IFN-y manufactured in Escherichia coli by
recombinant DNA technology and of >95% purity (7.2 X 106 U/mg) was kindly provided
by Dr. H . Michael Shepard, Genentech, Inc., South San Francisco, CA . NZB/W F, female
mice were given intraperitoneal injections of 5 X 104 U of rIFN-y or PBS three times
weekly for a period of 3 mo.
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FIGURE l .
￿
Survival of NZB/
W F, female mice treated
with IFN-y. 25 NZB/W F,
mice treated with IFN-y (0)
are compared with 25 age- and
sex-matched NZB/W F, ani-
mals given PBS (0) and to 16
NZW parental strain treated
with IFN-y (A). Arrows indi-
cate the time period of treat-
ment.
Monoclonal Antibodies.
￿
DB-1 is an IgGI mouse anti-rat IFN-y mAb that exhibits high-
affinity binding for rat and mouse IFN-y and efficiently neutralizes the antiviral activity
of both animal interferon species (6). TE33 is an IgGI mouse mAb specific to residues
50-64 of cholera toxin B subunit, and was used as a control antibody.
DB-1 monoclonal anti IFN-y antibodies were purified from ascites fluid of BALB/c
mice injected with 5 x 106 DB-1 hybridoma cells. Antibodies were purified by 45%
ammonium sulfate precipitation (twice) followed by chromatography on DEAE-Sephacel
column. The ability of DB-I to inhibit IFN-y-induced Ia expression was assayed in vitro
on the murine myelomonocytic cell line WEHI-3. Treatment of these cells with murine
IFN-y for 24-48 h induces the expression of la antigens on their surface (7). Treatment
of WEHI-3 cells with 10 U/ml of murine IFN-y in the presence of DB-1 at 0.5 mg/ml
caused inhibition of ^-70% of la expression as detected with fluorescein-conjugated MK-
D6 (anti-la') mAb on a FACS IV (Becton Dickinson & Co., Mountain View, CA).
Measurement of Anti-DNA Antibodies.
￿
Anti-DNA-specific antibodies in sera were as-
sayed by an ELISA as described (8).
Proteinuria.
￿
Proteinuria was measured colorimetrically by the use of Uristix (Miles
Laboratories Inc., Elkhart, IN).
Two groups of 25 female NZB/W F, mice, 4 mo old, received rIFN-y or
equivalent volumes of PBS over a period of 3 mo. As an additional control
group, 16 age- and sex-matched mice of the parental strain NZW, were similarly
treated with IFN--y . Death occurred at an earlier age in the NZB/W F, group
that received IFN-y compared with the PBS control mice (Fig. 1). The difference
in survival between treated and control mice was statistically significant (p <_
0.001).
While PBS-treated NZB/W F, control mice began to die at -8 mo of age (50%
survival, 9.5 mo), in the IFN-1-treated group 75-80% of NZB/W F, were dead
by 8 mo . The life span of the NZW control group was not affected by the IFN-
y treatment . High grade proteinuria was detected significantly earlier in the
IFN-y-treated NZB/W F, group compared with the control group (Fig. 2A).
The onset of death correlated closely with the onset and amount of proteinuria.
Similarly, anti-DNA antibodies reached peak levels earlier in the IFN-y treated-
group than in the control group (Fig. 2B), although no significant differences in
the peak levels of anti-DNA antibodies were observed between the two groups
as a whole .
In a separate experiment, treatment with IFN-y was initiated at different ages800
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FIGURE 2. (A) Cumulative frequency of
significant proteinuria (>>-3+) in NZB/W F,
mice treated with IFN-y (0), PBS or non-
relevant mAb (Q), or monoclonal anti-IFN-
y, either 3 times per week (/) or once per
week (p). Since no significant differences
were found between PBS- versus nonrele-
vant antibody-treated animals, theyare pre-
sented together as a single control group.
To reflectmore accurately thedevelopment
of renal disease in all mice (alive and dead),
a correction factor was induced. Thus,each
point reflects the current level of protein-
uria as well as the last measurement of pro-
teinuria in deceased mice. (B) Effect of the
various treatments on the appearance of
anti-DNA antibodies. The open bars repre-
sent the mean age at which anti-DNA anti-
bodies were detected in the various groups,
while dashed bars represent the mean age
± SD at which peak levels of anti-DNA
antibody occurred. Note that at the age
when anti-DNA antibody was detected, the
difference between the PBS- and the IFN-
y-treatedgroups is not significant, whilethe
difference between PBS- and DB-1-treated
groups is significant (p <- 0.05). The differ-
ences in age at peak levels between PBS-
treated versus IFN-y- or DB-1-treated
groups are significant (p < 0.005 and p :-
0.0005, respectively).
between 2.5 and 6 .5 mo, using the same treatment protocol . Treatment starting
at various ages between 2 .5 and 6 mo resulted in significantly earlier appearance
of high grade proteinuria and accelerated mortality when compared with age-
matched control groups. When IFN-y treatment started at 6 .5 mo, no significant
difference in lifespan was observed between treated and controls (not shown).
Given these results we asked whether we could block disease development by
using mAb to IFN-y. Two groups of 20 female NZB/W F, mice received purified
anti-IFN-y mAb (DB-1), and as controls, 10 mice received an irrelevant mono-
clonal IgGI antibody (TE33) and 20 animals received PBS. All mice were 4 mo
old at the beginning of the experiment. One group was treated with 2 mg DB-1
intraperitoneally three times per week and the other received 2 mg DB-1 once
a week. Treatment was given for a period of 3 mo.
Fig. 3 shows the improved survival rate of mice treated with DB-1 . At the age
of 11 mo, 80-85% of both control groups were dead, while 95% of mice were
alive in both DB-1-treated groups. No difference was found between mice given
weekly 2-mg injections of anti-IFN-y compared with those receiving 2 mg
antibody three times per week. In parallel with the dramatic prolonged survival
of DB-1-treated mice, the development of severe proteinuria was significantly
delayed (Fig. 2A). By 9 mo >60% in each control group had high grade
proteinuria, but none of the mice treated with DB-1 had proteinuria of this
degree. At the age of 11 mo ^-30-40% of treated animals showed severe
proteinuria . The titer of anti-DNA antibody reached maximal levels at 7-8 mo
in the control groups, while DB-1-treated animals showed similar levels at ^-10
mo of age (Fig. 2B). It is noteworthy that the PBS control group and the100
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FIGURE 3. Prolonged survival
￿
of
NZB/W F, mice treated with anti-IFN-
.y mAbs. Groups of 20 age-matched fe-
male mice were treated intraperitoneally
with PBS (A), nonrelevant mAb (O), or
with monoclonal anti IFN-,y either at 2
mg three times per week (/) or 2 mg
once per week (p).
irrelevant antibody control groups are very similar in terms ofsurvival, protein-
uria, and anti-DNA antibody profiles.
Discussion
During the past decade many diverse activities have been attributed to IFN-7.
Despite the ability of IFN-,y to mediate such a variety of functions, and to exert
remarkably pleomorphic effects on the immune system (9), surprisingly little is
known about the biological relevance ofIFN-,y to the homeostasis ofthe immune
system in vivo.
Two lines ofexperimental observations led us to undertake these experiments.
First, IFN-yhas been established as theprototype lymphokine to induce enhance-
ment of synthesis and surface expression of MHC class II antigens in a wide
variety of cell types both in vitro and in vivo (10, 11). Inappropriate expression
of MHC class II molecules has been shown in several autoimmune processes both
in animal models (12) and human diseases (13). Moreover, it seems possible that
the induction of MHC molecules is due to release of IFN-,y by activated T cells.
Thus, rat astrocytes induced in vitro to express la molecules by IFN-7 were able
to present myelin basic protein to encephalitogenic T cell lines in a MHC-
restricted manner (14). Second, studies in this laboratory have demonstrated
that in vivo administration ofmAbs specific for an Ia region gene product (I-A°)
induced remission in NZB/W F, mice with moderate renal disease (15). Anti-la
mAb therapy was effective in several other autoimmune disease models such as
experimental allergic encephalitis, experimentally induced myasthenia gravis,
and in spontaneous autoimmune diabetes and thyroiditis in BB/W rats.
Our results clearly suggest that IFN-,y might have a major biological role in
aberrant immune regulation causing the development ofmurine lupus nephritis.
The fact that administration of IFN-7 accelerated the development of the
nephritis does not by itself prove that this lymphokine has a major role in the
development of the disease, since other lymphokines and cellular factors share
some activities with IFN-y: thus, for example, in addition to IFN-y, class II MHC
expression has been enhanced by IFN-« or -S (16) and IL-4 (BSF-1) (17).
Therefore, the blocking of IFN-y might have no effect on other possible
regulatory factors and thus have no effect on the progression of the disease. On
the other hand, if antibody to IFN-7 is able to block or delay progression of
disease, this would argue in favor of IFN-,y playing a principal role in the802
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pathogenesis of the disease. Thus, the experiments with monoclonal anti-IFN-y
were essential to confirm this point.
Whether the results of this study are applicable in a more general sense to the
initiation and propagation of other autoimmune processes, or even during
normal ongoing immune responses, remains an open question at the present
time. Similarly the mechanism of IFN-y activity in this in vivo system remains to
be determined. While we favor the hypothesis that IFN-y activates the immune
system by upregulating class II MHC antigen expression as initially proposed by
Bottazzo et al . (18), it must be noted that IFN-y has both activating and inhibiting
effects on B cell differentiation and B cell responses, and at least some of the
autoimmune abnormalities in NZB/W F, mice may be attributed to B cell effects
(19). Alternatively, it is possible that IFN-y has an indispensable physiological
function that is entirely distinct from any yet defined.
In considering potential therapeutic applications of IFN-'r (20), our observa-
tions indicate that this lymphokine should not be considered exempt from
possible untoward consequences . The present study, coupled with other obser-
vations (21), suggests that IFN-y may be contraindicated in patients with certain
autoimmune diseases.
Conversely, we have shown that in vivo therapy with monoclonal anti-IFN-y
can significantly alter the course of murine lupus-like nephritis. This may have
implications for the treatment of SLE in man.
Summary
The (NZB X NZW)F, mouse is recognized as an important animal model of
the human disease systemic lupus erythematosus (SLE). Groups of NZB/W F,
mice were treated either with IFN-y or with PBS. The results demonstrate that
IFN-treated animals have accelerated development of fatal immune complex
glomerulonephritis relative to age-matched controls. On the other hand, admin-
istration of mAbs specific for IFN-y to such mice from 4 to 7 mo of age resulted
in significant remission. Development of both proteinuria and anti-DNA anti-
bodies were delayed and survival at 11 mo was increased from <20% to 95% in
treated mice relative to controls (p <_ 0.001). These findings may have therapeu-
tic implications for the treatment of SLE.
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